The FDA has just approved 68Ga-PSMA-11 at UCSF and UCLA. This is the first PSMA radiotracer approved. It is indicated at initial staging and at time of biochemical recurrence. .

We are looking to hire a Data Analyst to work with our team, to help analyze the PROGRESS database, the largest database of PSMA PET. We are looking for R coding and REDCap experience. Come understand how PSMA PET impacts patient outcomes! Apply @

Exciting 177Lu-PSMA-617 has been approved by the FDA for use prior to chemotherapy based on the PSMAfore results. Perfect timing, during day 1 of the @PSMAconference!

Looking forward to seeing everyone at the @PSMAconference starting Friday at UCLA. We have sold out all of our in person availability! If you haven’t registered, you can still join virtually (.

RT @UCSFimaging: The @PSMAconference will gather leading experts to discuss the latest in PSMA PET imaging & radioligand therapies. Hear fr….

We are excited to host the second PSMA PET conference with @UCLATheranostic and the @PCF_Science in March. The abstract deadline is January 10th (. We have an incredible line up of speakers from across the globe (. Please join us!

2) Post-treatment imaging is a unique aspect of lutetium-based theranostics, which is markedly cheaper than PET based imaging response. In 28%, progression was noted and treatment stopped, and in 20%, treatment was delayed due to good response (below).

1) We recently reported our experience with post-treatment SPECT in PSMA RLT and its impact on management. Nearly 50% of patients had a change in treatment! Post-treatment imaging has a huge impact, and allows us to follow disease at each treatment (.

I wanted to thank @SNM_MI and the ERF for selecting me as the Richard Wahl Mid-Career Leadership Awardee. It's a great honor to be associated with the Dr. Wahl in any manner, and I'm proud to have his mentorship over the years. Best part is this ridiculous video!

Excited to move forward with our work on FET PET in gliomas in collaboration with @TelixPharma, who announced our partnership a few weeks ago (. Hopefully this academic industrial partnership will help make this FET more widely available. More to come!

So posted 7 days in a row on LinkedIn and Twitter (completely duplicative). People have definitely moved from Twitter to LinkedIn. There were 2x more interactions (likes etc) and 2.7x more views on LinkedIn than on Twitter. Seems like the field is coalescing on LinkedIn.

Check out the manuscript, which shows that 27% of patients with NETs had their management changed base on the findings from post-treatment SPECT during PRRT. The most common change was stopping early due to response seen on imaging.

In March, @shiningsurekha published our experience on the impact of post-treatment SPECT on patient management. We are trying to move people from thinking about SPECT as only for dosimetry, and focus on its role in response assessment and using it to follow patients over time.

2) 61% of patients who did not meet VISION laboratory criteria achieved a PSA50 although had a shorter OS compared to those who did, and 3) we stopped treatment early in 19 patients due to good response and in the 10 who we have restarted in, 9 achieved a PSA50 on re-exposure.

Abuzar Moradi Tuchayi published his first first author paper in @JournalofNucMed describing our experiences using PSMA RLT @UCSFimaging. There were a number of findings: 1) 39% of patients who did not meet TheraP imaging criteria achieved a PSA50. (

Amazing meeting put on by @SNM_MI to bring together industry, academia and the @US_FDA. We had great collaborative discussions with our colleagues from the @FDAOncology and DIRM, which will help set the foundation for the future development of RLTs.

I was fortunate to visit Brazil and attend #JPR2024 to share our RLT experience. It was great to meet Raphael Lopes, Marcelo Queiroz, Daniela Ferraro and Christina Matushita. It’s eye opening to think about patient selection in a resource limited environment.

It is really remarkable how well you can visualize small subcentimeter nodes. It reminds me of the value of PSMA PET but in staging of bladder cancer. Hopefully we can move this forward soon to help get this study available to our patients.

During my hiatus from social media, we published our experience using 68Ga-FAP-2286 to stage bladder cancer in @JournalofNucMed. Thank you so much @koshkin85 and @SimaPorten for helping make it happen.

It was also great to see old friends like Chuck Ryan who apparently also shops at @elgansospain! Thank you so much to @Silke_Gillessen and @AOmlin for including me. If you want to see my talk, there's a facsimile available on @urotoday: